Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real‑world matched comparison of talquetamab versus teclistamab in Relapsed/Refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MFMohammad FaizanZKZainab Zaib KhanAHAli Shan Hafeez

Discussion

Loading...

Member takes

Overview

Real-world analysis compares talquetamab and teclistamab in relapsed/refractory multiple myeloma, indicating similar safety and efficacy profiles.

Key Points

  • Both drugs had comparable effectiveness and safety outcomes in matched cohorts of relapsed/refractory multiple myeloma patients.
  • Cytokine release syndrome occurred in 21.2% of talquetamab cases, compared to 13.9% in teclistamab cases, with similar rates of other adverse effects.
  • The analysis utilized propensity-score matching to balance variables across the two treatment cohorts, yielding clinically relevant results.
  • These findings suggest that treatment choice among bispecific monoclonal antibodies should consider patient-specific factors, including baseline marrow reserve.

Cite This Study

Faizan et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e086https://doi.org/10.1182/blood-2025-7577
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparison of talquetamab vs teclistamab in relapsed refractory multiple myeloma.2026
  2. 2Talquetamab outcomes from practice outside of clinical trials: The bital study2025
  3. 3Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-12025 · 15 citations
  4. 4Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma2025 · 1 citations
  5. 5Real-world efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: Results from 87 patients treated by the polish myeloma group2025